Loading
A phase 2 trial of Imatinib in metastatic cancer, run by Kumquat Biosciences Inc., now recruiting.
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line) is a phase 2 interventional study registered as NCT07406633 by Kumquat Biosciences Inc., with 46 participants planned, started 2026-06-23 and due to reach its primary completion in 2027-10. Interventions recorded: KQB198, Imatinib (Gleevec). Conditions listed: GIST - Gastrointestinal Stromal Tumor, GIST, GIST Metastatic Cancer, Gastro Intestinal Stromal Tumour. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Imatinib, Small-molecule kinase inhibitors.
Shares Imatinib, Small-molecule kinase inhibitors.
Shares Imatinib, Small-molecule kinase inhibitors.
Shares Imatinib, Small-molecule kinase inhibitors.
Shares Imatinib, Small-molecule kinase inhibitors.
Shares Imatinib, Small-molecule kinase inhibitors.
Shares Imatinib, Small-molecule kinase inhibitors.
Shares Imatinib, Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/